Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.61 |
| ▸ | DHODH | Q02127 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TACR3 | P29371 | 3/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | ACACA | Q13085 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873300 | 0.91 | ACHE (1.00) | ACHEKDM4ELMNASMN1; SMN2PDE10A | |
| SCHEMBL28516025 | 0.88 | ACHE (0.93) | ACHEKDM4ELMNASMN1; SMN2PDE10A | |
| SCHEMBL24505991 | 0.81 | ACHE (0.80) | ACHEKDM4ELMNASMN1; SMN2PDE10A | |
| SCHEMBL4143397 | 0.80 | ACHE (0.77) | ACHEKDM4ELMNASMN1; SMN2PDE10A | |
| SCHEMBL15919363 | 0.80 | ACHE (0.77) | ACHEKDM4ELMNASMN1; SMN2DHODH | |
| SCHEMBL28905536 | 0.78 | ACHE (0.73) | ACHEKDM4ELMNASMN1; SMN2DHODH | |
| SCHEMBL379807 | 0.77 | LMNA (0.76) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL29586433 | 0.77 | LMNA (0.76) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL4155489 | 0.77 | ACHE (0.72) | ACHEKDM4ELMNASMN1; SMN2DHODH | |
| SCHEMBL28506567 | 0.76 | KDM4E (0.71) | ACHEKDM4ELMNASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | claimed |
| EP-2451795-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | Ottawa Hospital Research Institute (CA) | 2012-05-16 | — | — | EP | claimed |
| WO-2011003191-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2011-01-13 | — | — | WO | claimed |
| EP-2451795-B1 | COMPOSITIONS AND USES FOR ENHANCING VIRUS PRODUCTION | OTTAWA HOSPITAL RES INST (CA) | 2016-07-13 | — | — | EP | disclosed |
| US-9283254-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2016-03-15 | — | — | US | disclosed |
| US-20150202240-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-07-23 | — | — | US | disclosed |
| US-8940291-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-01-27 | — | — | US | disclosed |
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | disclosed |
| EP-2451795-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | Ottawa Hospital Research Institute (CA) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011003191-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | HAVCR2, MAVS, TSG101 | ACHE 2423/4885KDM4E 3672/4885LMNA 1828/4885 |
| US-20150202240-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | HAVCR2, MAVS, TSG101 | ACHE 2423/4885KDM4E 3672/4885LMNA 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.